NEW YORK (CBS.MW) -- Shares of Schering-Plough climbed Tuesday after some analysts said a new cholesterol-lowering drug could help the company recover from its current regulatory and financial woes.

The top line jumps 11%. Schering-Plough (SGP) swung to a second-quarter profit, as sales rose a stronger-than-expected 11%. The Kenilworth, N.J., drug maker made $259 million, or 16 cents a share ...

Merck and Schering-Plough said that they would pay $41.5 million to settle suits claiming they delayed study results on their cholesterol drug Vytorin because the data was unfavorable.

BOSTON (MarketWatch) -- Schering-Plough Corp. reported dramatically improved first-quarter earnings on Thursday, indicating that the troubled drugmaker has finally turned the corner back to ...

Tom Koestler, the research chief at Schering-Plough, has a revealing way of describing the risk-benefit profile of prescription drugs at a time when so much emphasis is being placed on safety. He ...

Big Pharma got bigger yesterday with Merck's announcement that it will acquire rival Schering-Plough in a cash-and-stock transaction worth $41.1 billion. And it's being made easier courtesy of U.S ...

TRENTON, N.J. — Merck & Co. is buying Schering-Plough Corp. for $41.1 billion in stock and cash in a deal that gives the companies more firepower to compete in a drug industry facing slumping ...

Cramer's making a trade.Schering also has a solid clinical pipeline and CEO Fred Hassan has dramatically improved Schering's operating model since taking the helm in 2003. Schering is on track to ...

Kerry served as The Scientist ’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, ...

Today, the little company got a big dose of visibility and a vote of confidence from Schering-Plough, which agreed to a co-development deal with Novacea that eventually could be worth $500 million ...

Schering-Plough Corp.'s loss of patent protection on Claritin is turning into a textbook case of bad transition planning. The drug maker -- repeatedly failing to accurately predict how fast sales ...

Merck and Schering-Plough said that they would pay $41.5 million to settle suits claiming they delayed study results on their cholesterol drug Vytorin because the data was unfavorable.